News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Altimmune To Announce Second Quarter 2017 Financial Results On August 10



7/31/2017 1:14:15 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

GAITHERSBURG, Md., July 31, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced that it will report financial results for the three and six months ended June 30, 2017 before the market open, and host a conference call at 8:30am Eastern Time on Thursday, August 10th, 2017.

Conference Call Details
Date: Thursday, August 10
Time: 8:30am Eastern Time
Domestic: 888-599-8667
International: 719-325-4817
Conference ID: 8401203
Webcast: http://public.viavid.com/index.php?id=125554
Replays will be available through August 24th:
Domestic: 844-512-2921
International: 412-317-6671
Replay PIN: 8401203

About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease and on the development of two next-generation anthrax vaccines that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines. The company has two proprietary platform technologies, RespirVec and Densigen, each of which has been shown to activate the immune system in distinctly different ways than traditional vaccines.

Altimmune Contacts Bill Enright President and CEO Phone: 240-654-1450 Email: enright@altimmune.com Matthew Duffy Investor Relations Phone: 212-915-0685 Email: matthew@lifesciadvisors.com

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES